Peter Kaiser, MD and Saradha Chexal, MD discuss patient selection for geographic atrophy treatments.

Peter Kaiser, MD, and Chirag Jhaveri, MD, discuss gene therapy in wet AMD.

Peter Kaiser, MD, and Dilsher Dhoot, MD, discuss incorporating medications into treatment for macular degeneration.

Peter Kaiser, MD, and Priya Vakharia, MD, discuss the results from the GALE extension study.

Peter Kaiser, MD, and Veeral Sheth, MD, MBA, FACS, FASRS, discuss reducing injection burden and gene therapy.

Peter Kaiser, MD, and Arshad Khanani, MD, MA, FASRS, discuss new mechanisms of action in the management of retinal diseases.

Peter Kaiser, MD, and Arshad Khanani, MD, MA, FASRS, discuss new mechanisms of action in the management of retinal diseases.

Peter Kaiser, MD, and Yasha Modi, MD, discuss the impact of faricimab.

Peter Kaiser, MD, and Sruthi Arepalli, MD, discuss the relationship of IL-6 to macular edema and eye inflammation

Peter Kaiser, MD, and Christina Weng, MD, MBA, FASRS, discuss counseling patients on the variety of treatment options available

Peter Kaiser, MD, and Dilsher Dhoot, MD, discuss treatment for macular degeneration.

Peter Kaiser, MD, and Carl Regillo, MD, discuss the Port Delivery System

Peter Kaiser, MD, and Joseph Coney, MD, FACS, discuss Dr. Coney's mission trips to Haiti and the impact international retinal physicians are having there.

Peter Kaiser, MD, and María Berrocal, MD, discuss managing patients with Diabetic Macular Edema and proliferative disease with subhyaloid hemorrhage

Peter Kaiser, MD, and Robert Avery, MD, discuss incorporating new drugs into your practice.

Biosimilars for ranibizumab Peter Kaiser, MD

Pediatric patients and gene therapy Peter Kaiser, MD and Nina Berrocal, MD

Incorporating OCTA into your practice Peter Kaiser, MD and Jay Duker, MD

Brolucizumab safety Peter Kaiser, MD and Arshad Khanani, MD

Practice changes due to COVID-19 Peter Kaiser, MD & Christina Weng, MD

New treatments for dry AMD Peter Kaiser, MD

What’s new in pediatric retina

Gene therapy for macular degeneration

The utility of OCTA

Brolucizumab to treat wet AMD

The safety of brolucizumab

Close out AMD Awareness Month

New ways to treat nAMD patients

Tie2 pathway and why it's important

Unmet needs in macular degeneration

Clinical trials and real world outcomes

Highlighting key presentations from ASRS

Challenges in achieving treatment goals

Effects of missed anti-VEGF treatments

New drug therapies for diabetic macular edema

The use of steroids for the treatment of macular edema

Using a suprachoroidal needle to inject triamcinolon

Delivering triamcinolone to the suprachoroidal space

Discuss the use of a newly approved needle combined with a steroid for injections